ADVENTRX to Present at BIO CEO Conference
February 05 2007 - 12:17PM
PR Newswire (US)
SAN DIEGO, Feb. 5 /PRNewswire-FirstCall/ -- ADVENTRX
Pharmaceuticals, Inc. (AMEX:ANX), a biopharmaceutical research and
development company focused on commercializing anticancer and
antiviral therapies, announced today that Evan M. Levine, Chief
Executive Officer, will present a corporate overview at the 9th
Annual BIO CEO & Investor Conference on February 12th at
12:30pm EST. BIO CEO takes place in New York City at The Waldorf
Astoria Hotel, February 12-14, 2007. The BIO CEO conference is
hosted by the Biotechnology Industry Organization (BIO), an
organization focused exclusively on biotechnology. Attendees will
include institutional investors, industry analysts, venture
capitalists, investment bankers and other industry experts.
Additional conference details and online registration are available
at http://www.bio.org/. A live web cast of the presentation will be
available and can be accessed via the "Investors" section of the
Company's corporate web site at http://www.adventrx.com/ under
"Events." After the live web cast, the presentation will remain
available on the Company's web site for 14 days. About ADVENTRX
Pharmaceuticals ADVENTRX Pharmaceuticals is a biopharmaceutical
research and development company focused on commercializing
anticancer and antiviral therapies that improve the performance and
safety of existing treatments by addressing significant problems
such as drug metabolism, toxicity, bioavailability and resistance.
The Company's lead product candidate, CoFactor (ANX-510), is
currently being tested in a pivotal Phase III study for metastatic
colorectal cancer in the US. More information can be found on the
Company's corporate web site at http://www.adventrx.com/. Forward
Looking Statement ADVENTRX cautions you that statements included in
this press release that are not a description of historical facts
are forward-looking statements that involve risks, uncertainties,
assumptions and other factors that, if they do not materialize or
prove to be accurate, could cause ADVENTRX's results to differ
materially from historical results or those expressed or implied by
such forward-looking statements. The potential risks and
uncertainties that could cause actual results to differ materially
include, but are not limited to: uncertainties inherent in the drug
development process; the timing and success of clinical trials; the
validity of research results; the receipt of necessary approvals
from the FDA and other regulatory agencies; and other risks and
uncertainties more fully described in ADVENTRX's press releases and
public filings with the Securities and Exchange Commission.
ADVENTRX's public filings with the Securities and Exchange
Commission are available at http://www.sec.gov/. ADVENTRX does not
intend to update any forward-looking statement, including as set
forth in this press release, to reflect events or circumstances
arising after the date on which it was made. DATASOURCE: ADVENTRX
Pharmaceuticals, Inc. CONTACT: Investors, Ioana C. Hone of ADVENTRX
Pharmaceuticals, Inc., +1-858-552-0866; or Media, Amy Martini of
WeissComm Partners, +1-212-301-7223, for ADVENTRX Pharmaceuticals,
Inc. Web site: http://www.adventrx.com/ Company News On-Call:
http://www.prnewswire.com/gh/cnoc/comp/920134.html
Copyright
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jul 2023 to Jul 2024